The two paths in plain language
In 2026, a new GLP-1 patient chooses between two dominant access paths. Each has predictable strengths and weaknesses.
Telehealth bundle. A subscription that bundles an asynchronous or live video visit with a licensed clinician, a prescription (often compounded semaglutide or tirzepatide from a 503A pharmacy, or branded via LillyDirect referral post-delisting), shipping, and message-based support. Representative 2026 pricing: Hims weight-loss program $199–$349/mo, Ro Body Program $145/mo subscription + drug, Henry Meds $249–$399/mo bundled, Mochi Health $79/mo subscription + drug, Found, Sequence (WW Clinic).
In-person path. A primary-care physician, obesity-medicine specialist, or endocrinologist performs a traditional visit, writes a prescription that runs through your retail or mail-order pharmacy, and sees you quarterly. Typical costs: new-patient visit $200–$350 cash (or $30–$75 copay insured), follow-ups $100–$200 cash or $20–$50 copay. For insured patients with coverage, Wegovy or Zepbound copays commonly land at $25–$100/month with manufacturer savings cards; without coverage, expect $499 via LillyDirect or NovoCare vial self-pay, or $1,086–$1,349 at full list.
When telehealth wins on cost
Telehealth is almost always cheaper if you are uninsured or your commercial plan does not cover AOMs. The bundle absorbs the 503A compounded peptide at wholesale-tier pricing ($80–$140/month drug cost) and retails at $249–$399. Even at the high end, that beats $499 LillyDirect plus $200 quarterly clinic visits.
Telehealth also beats in-person on time cost. No travel, no waiting room, no PTO for a 15-minute visit. For busy working adults, the implicit hourly value saved is real.
When the in-person clinic wins
- You have commercial coverage for AOMs. Your $25–$100 copay on Wegovy or Zepbound beats any telehealth bundle. The clinic’s staff handles prior auth. See the prior-auth guide.
- You have type 2 diabetes or significant cardiometabolic disease.You need lab ordering, insulin dose coordination, and a longitudinal relationship. Telehealth can do labs but it’s piecemeal.
- You are over 65 on Medicare. Medicare Part D covers GLP-1s only for approved indications (T2D, CV risk reduction per SELECT, OSA per SURMOUNT-OSA). Telehealth cannot reliably get Wegovy or Zepbound approved on Medicare.
- Complex interactions or contraindications. Personal/family MTC/MEN2, prior pancreatitis, or brittle diabetes warrants an in-person evaluation.
- You need a multidisciplinary approach. Bariatric-surgery candidacy, registered dietitian, behavioral therapy — most insurance networks route these as in-person referrals.
The quality dimension most cost comparisons skip
Telehealth GLP-1 programs vary enormously in clinical rigor. Good ones require labs at baseline and every 6 months, screen for contraindications, slow titration when side effects appear, and put a live clinician behind clinical messaging. Less-good ones issue a prescription based on a 3-question intake form and staff a call center. Use the checklist above to separate the two before you pay.
Hybrid: the emerging winner for many patients
A pattern that has emerged in 2025–2026: use a telehealth platform for drug and convenience, and maintain a primary-care or obesity-medicine relationship for labs, comorbidity management, and paper-trail continuity. The hybrid adds $200–$400/year (two PCP visits with labs) but preserves continuity of care and positions you for insurance coverage later if you qualify. If your PCP is in-network, this hybrid is often the best value.
What the trials implicitly assume about care setting
STEP 1, STEP 2, STEP 3, SURMOUNT-1, and SELECT all enrolled through academic medical centers or large multi-site networks. Visits were quarterly or more frequent with a trained obesity-medicine or endocrinology investigator. Labs at baseline, week 12, 24, 52, and 68/72. Side effects managed proactively. When you read “14.9% TBWL on semaglutide” or “22.5% on tirzepatide 15 mg,” that efficacy was achieved with high-touch care. Real-world outcomes on both telehealth and in-person paths trail trial means for predictable reasons: adherence gaps, dose-escalation interruptions from side effects, discontinuation. A 2024 Blue Cross analysis found fewer than 25% of commercial Wegovy/Zepbound starters remained on therapy at 12 months.
The insurance coverage lever is enormous
KFF’s 2024 employer-survey data showed roughly 18% of large employers covered GLP-1s for weight loss; that figure reached ~34% by Q4 2025 and is climbing. If your plan is in the covered bracket, the in-person path with manufacturer savings-card stacking ($25–$50/month) produces a cost-per-pound below $20 — unreachable by any cash telehealth path. See the insurance coverage checker. Covered: in-person wins in a landslide. Not covered: telehealth usually wins year one.
Running the math the right way
Defaults above: $299 telehealth bundle vs $60 clinic visit × 4 visits/yr plus $499/month via LillyDirect. Telehealth annual = $3,588. In-person annual = $240 visits + $5,988 drug = $6,228. Telehealth wins by ~$2,640. Swap the $499 drug for a $50 insurance copay and in-person annual = $240 + $600 = $840, saving ~$2,748 vs telehealth. The answer depends entirely on your drug cost path.